Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer

Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer

Post Views: 106 Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced the appointment of Hendrik Nogai, M.D. to the role of Chief Medical Officer effective February 1st, 2022. Dr. Nogai will lead medical, clinical, and regulatory functions to…